Allecra Therapeutics

Phase 3

Saint-Louis, FranceFounded 2013allecra.com

Addressing a Major Unmet Need in Overcoming Antibiotic Resistance Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam,has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled Phase 3 trial, and the Company is preparing submis...

Founded

2013

Focus

Small Molecules

About

Addressing a Major Unmet Need in Overcoming Antibiotic Resistance Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam,has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled Phase 3 trial, and the Company is preparing submis...

Funding History

2

Total raised: $65M

Series B$40MAndera PartnersMay 15, 2022

Series A$25MAndera PartnersSep 15, 2020

Company Info

TypePrivate

Founded2013

LocationSaint-Louis, France

StagePhase 3

Contact

Sectors

Small Molecule Drugs

SIMILAR COMPANIES

Phase 2 · Lille

Pre-clinical · Lyon

ABL Diagnostics

Pre-clinical · Strasbourg

Acticor Biotech

Pre-clinical · Paris

Pre-clinical · Lyon

Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.